The biosimilar Enoxa (enoxaparin), marketed in Tunisia, demonstrated equivalence in preventing subclinical postoperative thrombotic events in patients with digestive cancers to Sanofi’s Lovenox, in a randomized controlled trial.
The biosimilar Enoxa (enoxapain biosimilar, Medis Pharmaceuticals), marketed in Tunisia, demonstrated equivalence in preventing subclinical postoperative thrombotic events in patients with digestive cancers to Sanofi’s Lovenox, in a randomized controlled trial published in PLOS ONE.
Both cancer and major surgery increase the risk of venous thromboembolic disease (VTED), including deep vein thrombosis and pulmonary embolism: cancer induces hypercoagulability, and surgery causes vascular injury that is often followed by a period of immobilization. VTED is the second leading cause of death in patients with cancer, the authors noted.
Thromboprophylaxis reduces the risk of VTED following surgery, and several molecules for this purpose are available, including enoxaparin, a low-molecular weight heparin (LMWH). Multiple biosimilar enoxaparin products are available, including Inhixa and Thorinane in the EU, Fragmin and Innohep in the US, and Cloti-Xa in India. Enoxa has been available in Tunisia since 2007.
This randomized controlled trial in a single center in Tunisia evaluated equivalence of Enoxa to the reference product in patients following surgery for digestive cancers. Patients received one injection of either originator or biosimilar enoxaparin daily for 30 days starting 8-12 hours after surgery. The primary outcome of the study was asymptomatic thromboembolic events assessed by Doppler ultrasound of the lower limbs 7-10 days following surgery, and secondary endpoints included symptomatic thrombotic events, heparin-induced thrombocytopenia, bleeding events, and deaths. A total of 168 patients were enrolled, and 145 patients were evaluated by Doppler ultrasound, 74 in the biosimilar group and 71 in the reference product group.
There were no statistically significant differences between groups for demographics and thrombosis-associated factors, such as history of cardiovascular disease and stroke, or use of hormone replacement therapy.
Six (4.1%) of the 168 enrolled patients had subclinical venous thrombosis following surgery, 2 (2.7%) in the biosimilar group and 4 (5.6%) in the originator group. The 95% CI of the difference in means between groups (-0.095 to 0.036) fell within the margins of equivalence (-0.20 to 0.20).
Clinical and subclinical events combined occurred in 6 (6.9%) and 7 (8.6%) patients in the biosimilar and reference product groups, also with no significant difference between groups. There were also no significant differences in other secondary outcomes, such as postoperative bleeding, heparin-induced thrombocytopenia, post-operative complications, and deaths. The authors noted the overall mortality rate (10.1%) was high. However, it was not significantly different between groups. Deaths occurred in 12.6% of patients who received the biosimilar and 7.4% in those who received the reference product.
The authors concluded Enoxa met equivalence criteria, and noted their results are consistent with 2 non-comparative studies that found Enoxa was safe and effective for preventing thrombotic events in patients undergoing total hip replacement. To their knowledge, theirs is the first trial to compare Enoxa to the reference product for preventing post-operative, subclinical thrombotic events.
Reference
Dziri C, Ben Hmida W, Dougaz W, Khalfallah M, Samaali I, Jerraya H, Bouasker I, Nouira R. Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial. PLoS One. 2023;18(11):e0293269. doi:10.1371/journal.pone.0293269
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.